Goldman Sachs Group set a GBX 4,080 ($53.15) target price on AstraZeneca (LON:AZN) in a report released on Wednesday morning. The firm currently has a sell rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. Jefferies Financial Group raised their price objective on shares of AstraZeneca from GBX 5,950 ($77.50) to GBX 6,000 ($78.16) and gave the company a buy rating in a research note on Friday, June 15th. Berenberg Bank reiterated a buy rating and issued a GBX 6,200 ($80.76) price objective on shares of AstraZeneca in a research note on Friday, June 8th. Citigroup reiterated a buy rating on shares of AstraZeneca in a research note on Friday, June 8th. JPMorgan Chase & Co. reiterated a buy rating on shares of AstraZeneca in a research note on Wednesday, June 6th. Finally, Deutsche Bank reiterated a buy rating on shares of AstraZeneca in a research note on Wednesday, June 6th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of GBX 5,689.45 ($74.11).

Shares of LON AZN opened at GBX 5,918 ($77.09) on Wednesday. AstraZeneca has a 52 week low of GBX 4,260 ($55.49) and a 52 week high of GBX 5,520 ($71.90).

The firm also recently announced a dividend, which was paid on Monday, September 10th. Shareholders of record on Thursday, August 9th were given a dividend of GBX 68.40 ($0.89) per share. This represents a yield of 1.19%. The ex-dividend date of this dividend was Thursday, August 9th.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: How Do You Calculate Return on Equity (ROE)?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.